Stifel analyst Andrew Partheniou lowered the firm’s price target on Green Thumb Industries to C$22 from C$30 and keeps a Buy rating on the shares. The firm is reducing its broader core MSO market estimates by 9% in 2024 and modifying its valuation methodology for U.S. cannabis producers for “low growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GTBIF:
- Green Thumb to Open RISE Dispensary Las Vegas on Craig, its 84th Retail Location in the Nation, on August 2nd
- Rising High: Exclusive talk with biotech company Tryp Therapeutics
- Rising High: Exclusive talk with biotech company Enveric Biosciences
- Rising High: Exclusive talk with mental healthcare company Numinus
- RISE Dispensaries Ironically “Celebrates” Richard Nixon with “Thanks, Dick” Campaign